CMS is brokering outcomes-based agreements on behalf of Medicaid programs. Thirty-three states, along with Washington, D.C., ...

In this interview, Matthew Yarnell, president of SEIU Healthcare, Pennsylvania, a healthcare union, condemns Trump’s $1 ...

The response rate to Amtagvi was higher in patients who had received two or fewer therapies than in those with more heavily ...

While successes have been seen because of HIV self-testing, funding cuts to USAID and PEPFAR will make continued research difficult, according to Anna Bershteyn, Ph.D., associate professor in the ...

According to experts at the IAS 2025 meeting in Kigali, Rwanda, AI revolutionizes HIV vaccine development by enhancing design ...

Experts, such as Lloyd Mulenga, M.Sc., M.B., Ch.B., Ph.D., discuss long-acting injectable HIV PrEP's potential in Zambia, ...

The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...

A separate analysis of the real-world trial found that those who switched from daily antiretroviral treatment to Cabenuva had fewer concerns about treatment.

A larger role for China, perhaps, and the fraught issue of integrating HIV services into services for other diseases.

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

Investigational interstitial lung disease (ILD) drug, efzofitimod, shows early signs of efficacy in patients with pulmonary ...